Associated Papers
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A et al.
Oncotarget, 2021
33889302 (PubMed )
Supplement: oncotarget-12-791-s001.pdf
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D et al.
Cancer Science, 2020
31828882 (PubMed )
Supplement: CAS-111-667-s002.xlsx › Table_S2
Select a paper to view details